Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
4.520
+0.110 (2.49%)
At close: Jul 21, 2026, 4:00 PM EDT
4.480
-0.040 (-0.88%)
After-hours: Jul 21, 2026, 4:05 PM EDT
Arbutus Biopharma Employees
Arbutus Biopharma had 19 employees as of December 31, 2025. The number of employees decreased by 25 or -56.82% compared to the previous year.
Employees
19
Change (1Y)
-25
Growth (1Y)
-56.82%
Revenue / Employee
$10,076,053
Profits / Employee
$8,458,947
Market Cap
892.87M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 19 | -25 | -56.82% | 19 | 0 |
| Dec 31, 2024 | 44 | -29 | -39.73% | 44 | 0 |
| Dec 31, 2023 | 73 | -25 | -25.51% | 73 | 0 |
| Dec 31, 2022 | 98 | 11 | 12.64% | 96 | 2 |
| Dec 31, 2021 | 87 | 9 | 11.54% | 85 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 465 |
| Pharming Group | 407 |
| Phathom Pharmaceuticals | 371 |
| Geron | 258 |
| DBV Technologies | 161 |
| Sana Biotechnology | 142 |
| Solid Biosciences | 121 |
| Odyssey Therapeutics | 100 |
ABUS News
- 5 days ago - Arbutus Biopharma expects to return $230M in capital to shareholders - TheFly
- 5 days ago - Arbutus initiates patent infringement actions against Pfizer, BioNTech - TheFly
- 5 days ago - Arbutus Biopharma receives $178M settlement agreement from Moderna - TheFly
- 5 days ago - Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders - GlobeNewsWire
- 2 months ago - Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Arbutus Biopharma Quarterly report: Q1 2026 - Filings
- 2 months ago - Arbutus Biopharma Earnings release: Q1 2026 - Filings
- 3 months ago - Arbutus Biopharma granted Fast Track designation for imdusiran - TheFly